Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Cost Effectiveness Gene Therapy Pricing Strategies

ICER Analyses Increasingly Guide US Price Negotiations, Payers Report

  • Analysis

Executive Summary

Nearly 65% of respondents reported ICER cost effectiveness reviews are 'likely' or 'extremely likely' to function as a benchmark in price negotiations with manufacturers, according to a recent survey.

You may also be interested in...



ICER Value Framework Update Reaffirms Support For Real-World Evidence

Drug makers have sought a larger role for RWE in ICER's review process; proposed update also includes process to re-evaluate cost-effectiveness evidence after one year.

ICER Value Assessments Could Provide US Standard, Payers, Providers Tell HHS

Comments to HHS on the Trump Administration’s US drug pricing blueprint recommend that cost effectiveness analyses by the Institute for Clinical and Economic Review could help promote value-based pricing.

Medicare Retail Drug Spending Accelerates In 2018 Despite Price Declines

Prices for retail drugs across US payers decreased for the first time in years, driven by a drop in generic prices and “little to no growth” in prices for brands.

Table

View full table

Topics

Tags:
Cost Effectiveness Gene Therapy Pricing Strategies
UsernamePublicRestriction

Register

PS140940

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By